Design and rationale of FOCUS (PX-171-011): A randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM)

BMC Cancer

Roman Hájek³  Richard Bryce⁴  Sunhee Ro²  Barbara Klencke²  Heinz Ludwig¹ 

[1] Wilhelminen Hospital, Vienna, Austria

[2] Onyx Pharmaceuticals, Inc, South San Francisco, CA, USA

[3] University Hospital Brno and Faculty of Medicine Ostrava, Department of Internal Medicine -Haematooncology, Jihlavska 20, Brno, 625 00, Czech Republic

[4] Present affiliation: Puma Biotechnology, Inc, Los Angeles, CA, USA

关键词: Overall survival;    Refractory;    Relapsed;    Phase 3 trial;    Proteasome inhibitor;    Multiple myeloma;   

Others  :  1080194
DOI  :  10.1186/1471-2407-12-415

 received in 2012-02-16, accepted in 2012-07-31,  发布年份 2012

【 摘 要 】

Background

Carfilzomib is a next-generation proteasome inhibitor with single-agent activity in patients with relapsed and refractory multiple myeloma (R/R MM). In PX-171-003-A1, a single-arm phase 2 study of carfilzomib monotherapy in heavily pretreated patients, the overall response rate was 23.7%, 37% of patients achieved ≥ minimal response and median overall survival (OS) was 15.6 months. Based on this study, carfilzomib was recently approved by the US Food and Drug Administration for the treatment of R/R MM. Herein we describe the trial design and rationale for a phase 3 randomized study, FOCUS (Car

F

ilz

O

mib for Advan

C

ed Refractory M

U

ltiple Myeloma European

S

tudy), being conducted to compare OS after treatment with single-agent carfilzomib to best supportive care (BSC) regimen in R/R MM.

Methods

Patients must have received ≥3 prior regimens, must be responsive to at least 1 line of therapy, and be refractory to their most recent therapy. Eligible patients are randomized 1:1 to receive either carfilzomib (28-day cycles at 20 mg/m² IV on Days 1–2 of Cycle 1, escalating to 27 mg/m² IV on Days 8, 9, 15, and 16 and continuing at 27 mg/m² through Cycle 9 and Days 1, 2, 15, and 16 ≥ Cycle 10) or an active BSC regimen (corticosteroid treatment of prednisolone 30 mg, dexamethasone 6 mg, or equivalent every other day with optional cyclophosphamide 50 mg PO once daily). Patients will continue treatment until disease progression, unacceptable toxicity, or treatment discontinuation and will then enter long-term follow-up for survival. The primary endpoint is OS and secondary endpoints include progression-free survival, overall response rate, and safety. Disease assessments will be determined according to the International Myeloma Working Group Uniform Response Criteria with minimal response per European Blood and Marrow Transplantation Group criteria.

Conclusions

This phase 3 trial will provide more rigorous data for carfilzomib, as this is the first carfilzomib study with OS as the primary endpoint and will not be confounded by crossover and will provide more robust secondary response and safety results that will add to the data set from prior phase 2 studies. FOCUS will facilitate regulatory approvals around the world and expand treatment options for patients with R/R MM.

Trial registration

EudraCT No. 2009-016840-38; NCT01302392.

【 授权许可】

   
2012 Hajek et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Dimopoulos MA, Terpos E: Multiple myeloma. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO 2010, 21(suppl 7):vii143-vii150.
• [2]Becker N: Epidemiology of multiple myeloma. Recent results in cancer research Fortschritte der Krebsforschung Progres dans les recherches sur le cancer 2011, 183:25-35.
• [3]Boyle P, Ferlay J: Cancer incidence and mortality in Europe, 2004. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO 2005, 16(3):481-488.
• [4]Palumbo A, Anderson K: Multiple myeloma. New Engl J Med 2011, 364:1046-1060.
• [5]Ludwig H, Beksac M, Blade J, Boccadoro M, Cavenagh J, Cavo M, Dimopoulos M, Drach J, Einsele H, Facon T, Goldschmidt H, Harousseau JL, Hess U, Ketterer N, Kropff M, Mendeleeva L, Morgan G, Palumbo A, Plesner T, San Miguel J, Shpilberg O, Sondergeld P, Sonneveld P, Zweegman S: Current multiple myeloma treatment strategies with novel agents: a European perspective. Oncologist 2010, 15(1):6-25.
• [6]Ludwig H, Beksac M, Blade J, Cavenagh J, Cavo M, Delforge M, Dimopoulos M, Drach J, Einsele H, Facon T, Goldschmidt H, Harousseau JL, Hess U, Kropff M, Leal Costa F da, Louw V, Magen-Nativ H, Mendeleeva L, Nahi H, Plesner T, San-Miguel J, Sonneveld P, Udvardy M, Sondergeld P, Palumbo A: Multiple myeloma treatment strategies with novel agents in 2011: a European perspective. The Oncologist 2011, 16(4):388-403.
• [7]Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, LeLeu X, Hulin C, Klein SK, Sonneveld P, Siegel D, Blade J, Goldschmidt H, Jagannath S, Miguel JS, Orlowski R, Palumbo A, Sezer O, Rajkumar SV, Durie BG: Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK 2012, 26(1):149-157.
• [8]Mehta J, Cavo M, Singhal S: How I treat elderly patients with myeloma. Blood 2010, 116(13):2215-2223.
• [9]Arastu-Kapur S, Shenk KD, Kirk CJ, Swinarski D, Muchamuel T, Bennett MK, Parlati F: Non-proteasome targets of proteasome inhibitors bortezomib and carfilzomib. Haematologica 2009, 94(s2):A0939.
• [10]Arastu-Kapur S, Anderl JL, Kraus M, Parlati F, Shenk KD, Lee SJ, Muchamuel T, Bennett MK, Driessen C, Ball AJ, Kirk CJ: Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clinical cancer research: an official journal of the American Association for Cancer Research 2011, 17(9):2734-2743.
• [11]Yang J, Wang Z, Fang Y, Jiang J, Zhao F, Wong H, Bennett MK, Molineaux CJ, Kirk CJ: Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats. Drug metabolism and disposition: the biological fate of chemicals 2011, 39(10):1873-1882.
• [12]Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN, Jiang J, Laidig GJ, Lewis ER, Parlati F, Shenk KD, Smyth MS, Sun CM, Vallone MK, Woo TM, Molineaux CJ, Bennett MK: Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 2007, 67(13):6383-6391.
• [13]Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, Demo SD, Bennett MK, van Leeuwen FW, Chanan-Khan AA, Orlowski RZ: Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 2007, 110(9):3281-3290.
• [14]O'Connor OA, Stewart AK, Vallone M, Molineaux CJ, Kunkel LA, Gerecitano JF, Orlowski RZ: A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clinical cancer research: an official journal of the American Association for Cancer Research 2009, 15(22):7085-7091.
• [15]Alsina M, Trudel S, Furman RR, Rosen PJ, O'Connor OA, Comenzo RL, Wong AF, Kunkel LA, Molineaux CJ, Goy A: A phase 1 single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. Clinical cancer research: an official journal of the American Association for Cancer Research 2012. Epub August 21, 2012
• [16]Jain S, Diefenbach C, Zain J, O'Connor OA: Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma. Core evidence 2011, 6:43-57.
• [17]Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Kunkel L, Wear S, Wong AF, Orlowski RZ, Jagannath S: A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 2012. Epub July 25
• [18]Papadopoulos KP, Lee P, Singhal S, Holahan JR, Tolcher AW, Patnaik A, Vesole DH, Rosen S, Rosen J, Bilotti EA, Woo T, Lee S, Hannah AL, Siegel DS: PX-171-007: A phase 1B study evaluating the safety and efficacy of a 30-minute IV infusion of carfilzomib in patients with relapsed and/or refractory (R/R) multiple myeloma (MM). Haematologica 2011, 96(Supplement 2):0898.
• [19]Vij R, Siegel D, Jagannath S, Jakubowiak A, Stewart A, McDonagh K, Bahlis N, Belch A, Kunkel L, Wear S, Wong A, Wang M: An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol 2012. 158(6):739-748
• [20]Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK, Kukreti V, Jagannath S, McDonagh KT, Alsina M, Bahlis NJ, Reu FJ, Gabrail NY, Belch A, Matous JV, Lee P, Rosen P, Sebag M, Vesole DH, Kunkel LA, Wear SM, Wong AF, Orlowski RZ, Siegel DS: An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood 2012, 119(24):5661-5670.
• [21]Niesvizky R, Vij R, Martin T, Zonder J, Wang Z, Woo T, Wong A, Badros A: Carfilzomib pharmacokinetics, safety, and activity in patients with relapsed or refractory multiple myeloma and renal dysfunction: final results. Haematologica 2011, 96(Supplement 2):370. Abstract 0890
• [22]Jagannath S, Singhal S, Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, Kukreti V, Bahlis N, Chanan-Khan A, Alsina M, Somlo G, Buadi F, Reu F, Song K, Kunkel L, Wong A, Vallone M, Orlowski R, Stewart AK, The Multiple Myeloma Research Consortium: Long-term follow-up in PX-171-003-A1, an open-label, single-arm phase 2 study of carfilzomib in patients with relapsed and refractory multiple myeloma (R/R MM): analysis by subgroups of interest. Haematologica 2011, 96(Supplement 2):0308.
• [23]Singhal SB, diCapua Siegel DS, Martin T, Vij R, Wang M, Jakubowiak AJ, Lonial S, Kukreti V, Zonder JA, Wong AF, McCulloch L, Kauffman M, Badros AZ, Niesvizky R, Orlowski RZ, Stewart AK, Jagannath S: Pooled safety analysis from phase (ph) 1 and 2 studies of carfilzomib (CFZ) In patients with relapsed and/or refractory multiple myeloma (MM). Blood 2010, 116(21):1954.
• [24]Singhal S, Siegel D, Martin T, Vij R, Wang M, Jakubowiak A, Lonial S, Kukreti V, Zonder J, Wong A, McCulloch L, Badros A, Niesvizky R, Orlowski R, Stewart A, Kotlovker D, Jagannath S: Integrated safety data from phase 2 studies of monotherapy carfilzomib in patients with relapsed and refractory multiple myeloma (MM): an updated analysis. Blood 2011, 118:1876.
• [25]Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV: International uniform response criteria for multiple myeloma. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK 2006, 20(9):1467-1473.
• [26]Kyle RA, Rajkumar SV: Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK 2009, 23(1):3-9.
• [27]Bladé J, Samson D, Reece D, Apperley J, Björkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D: Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high dose therapy and haempotietic stem cell transplantation. Br J Haematol 1998, 102(2):1115-1123.
• [28]Siegel D, Lee P, Singhal S, Holahan J, Tolcher A, Patnaik A, Vesole D, Rosen S, Rosen P, Bilotti E, Lee S, Woo T, Hannah A, Papadopoulos K: Phase (ph) 1b evaluation of the safety and efficacy of a 30-minute IV infusion of carfilzomib (CFZ) in patients (pts) with relapsed and/or refractory (R/R) multiple myeloma (MM). Haematology 2011, 96(Supplement 1):309.
• [29]Siegel D, Kaufman JL, Wang M, Martin T, Jagannath S, Niesvizky R, Reu F, Alsina M, Badros A, Gabrail N, Kukreti V, Singhal S, Le M, Kotlovker D, Bomba D, Hannah A, Vij R: Carfilzomib (CFZ) in patients with relapsed and/or refractory multiple myeloma (R/R MM): summary of safety and efficacy data upon long-term treatment. Haematologica 2011, 96(Supplement 1):1535.
• [30]Brandes LJ, Israels LG: Weekly low-dose cyclophosphamide and alternate-day prednisone: an effective low toxicity regimen for advanced myeloma. Eur J Haematol 1987, 39(4):362-368.
• [31]de Weerdt O, van de Donkb NWCJ, Veth G, Bloem AC, Hagenbeek A, Lokhorst HM: Continuous low-dose cyclophosphamide-prednisone is effective and well tolerated in patients with advanced multiple myeloma. The Netherlands Journal of Medicine 2001, 59:50-56.
• [32]Zhou F, Guo L, Shi H, Lin C, Hou J: Continuous administration of low-dose cyclophosphamide and prednisone as a salvage treatment for multiple myeloma. Clinical lymphoma, myeloma & leukemia 2010, 10(1):51-55.